{"id":"metformin-pioglitazone-exenatide","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Fluid retention/edema"}]},"_chembl":{"chemblId":"CHEMBL595","moleculeType":"Small molecule","molecularWeight":"356.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity. Pioglitazone is a thiazolidinedione that acts as a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist to enhance insulin sensitivity in target tissues. Exenatide is a GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, inhibits glucagon, and slows gastric emptying.","oneSentence":"This triple-agent combination improves blood glucose control through three complementary mechanisms: metformin reduces hepatic glucose production, pioglitazone increases insulin sensitivity in muscle and fat, and exenatide stimulates insulin secretion in response to glucose.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:54:35.523Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT04027023","phase":"PHASE4","title":"Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sciema UG","startDate":"2019-10-30","conditions":"Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT00765817","phase":"PHASE3","title":"Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-10","conditions":"Type 2 Diabetes","enrollment":261},{"nctId":"NCT02887625","phase":"NA","title":"Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM","status":"UNKNOWN","sponsor":"Dr. Muhammad Abdulghani","startDate":"2015-02","conditions":"Type 2 Diabetes","enrollment":410},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT00806520","phase":"","title":"Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":16},{"nctId":"NCT00676338","phase":"PHASE3","title":"Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Type 2 Diabetes Mellitus","enrollment":820},{"nctId":"NCT00637273","phase":"PHASE3","title":"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT01064687","phase":"PHASE3","title":"A Study in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":978}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"metformin\\pioglitazone\\exenatide","genericName":"metformin\\pioglitazone\\exenatide","companyName":"The University of Texas Health Science Center at San Antonio","companyId":"the-university-of-texas-health-science-center-at-san-antonio","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-agent combination improves blood glucose control through three complementary mechanisms: metformin reduces hepatic glucose production, pioglitazone increases insulin sensitivity in muscle and fat, and exenatide stimulates insulin secretion in response to glucose. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}